Does Haemonetics (HAE) Have Enduring Growth Potential?

Does Haemonetics (HAE) Have Enduring Growth Potential? Soumya Eswaran Thu, May 21, 2026 at 9:48 PM GMT+7 3 min read HAE Aristotle Capital Boston, LLC, an investment advisor, released its first-quarter 2026 investor letter for “Small Cap Equity Fund”. A copy of the letter is available to download here. U.S. small-cap equities delivered strong performance in the first quarter amid macroeconomic and geopolitical volatility, outpacing large-cap stocks. Improving earnings, attractive relative valuations, and a focus on domestic sectors supported the small caps in the quarter. In this backdrop, the Aristotle Small Cap Equity Fund (Class I-2) delivered a total return of 1.50% in the quarter, outperforming the Russell 2000 Index’s 0.89% return. The performance was supported by security selection in the information technology and financials sectors, along with underweight allocations to healthcare and industrials. The fund remains optimistic about the long-term outlook for U.S. small-cap equities. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.

In its first-quarter 2026 investor letter, Aristotle Small Cap Equity Fund highlighted stocks like Haemonetics Corporation (NYSE:HAE). Haemonetics Corporation (NYSE:HAE) is an innovative medical technology company that provides solutions for improving patient care. On April 20, 2026, Haemonetics Corporation (NYSE:HAE) closed at $59.56 per share. One-month return of Haemonetics Corporation (NYSE:HAE) was 0.10%, and its shares lost 9.98% over the past 52 weeks. Haemonetics Corporation (NYSE:HAE) has a market capitalization of $2.71 billion.

Aristotle Small Cap Equity Fund stated the following regarding Haemonetics Corporation (NYSE:HAE) in its Q1 2026 investor letter: